Analyst Reco. Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Real-time Estimate Cboe BZX Other stock markets 11:09:03 2024-05-20 am EDT			5-day change	1st Jan Change
37.34 ^USD	-1.23%		-0.03%	+71.89%

May. 15	Spyre Therapeutics, Inc. Announces Board Changes	CI
May. 13	Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating	May. 13	MT
Baird Starts Spyre Therapeutics With Outperform Rating, $50 Price Target	May. 02	MT
Stifel Adjusts Spyre Therapeutics' Price Target to $54 From $36, Maintains Buy Rating	Mar. 26	MT
Wells Fargo Upgrades Spyre Therapeutics to Overweight From Equalweight, Raises Price Target to $35 From $12	Mar. 01	MT
BTIG Initiates Spyre Therapeutics With Buy Rating, Price Target is $32	Dec. 20	MT
Stifel Adjusts Price Target on Spyre Therapeutics to $27 From $23, Keeps Buy Rating	Dec. 18	MT
Jefferies Initiates Spyre Therapeutics at Buy Rating With $31 Price Target	Dec. 11	MT
Wells Fargo Adjusts Price Target on Aeglea BioTherapeutics to $0.50 From $0.35, Maintains Equal-Weight Rating	23-08-16	MT
Stifel Initiates Aeglea BioTherapeutics With Buy Rating, $0.90 Price Target	23-07-25	MT
LifeSci Capital Downgrades Aeglea BioTherapeutics to Market Perform From Outperform	23-04-12	MT
JonesTrading Downgrades Aeglea BioTherapeutics to Hold From Buy	23-04-12	MT
Piper Sandler Lifts Aeglea BioTherapeutics to Overweight From Neutral, Price Target to $1.50 From $1	22-10-28	MT
Wells Fargo Lifts Aeglea BioTherapeutics to Overweight From Equalweight, Price Target to $2 From $1.50	22-10-28	MT
Needham Downgrades Aeglea BioTherapeutics to Hold From Buy	22-06-03	MT
Piper Sandler Downgrades Aeglea BioTherapeutics to Neutral From Overweight, Cuts Price Target to $1 From $4, Shares Dive 46%	22-06-02	MT
HC Wainwright Downgrades Aeglea BioTherapeutics to Neutral From Buy, Cuts Price Target to $1 From $17	22-06-02	MT
Piper Sandler Adjusts Price Target for Aeglea BioTherapeutics to $4 From $7, Maintains Overweight Rating	22-05-23	MT
Piper Sandler Adjusts Aeglea BioTherapeutics' Price Target to $7 From $9, Reiterates Overweight Rating	22-05-09	MT
HC Wainwright Adjusts Price Target on Aeglea BioTherapeutics to $17 From $20, Reiterates Buy Rating	22-05-06	MT
AEGLEA BIOTHERAPEUTICS : HC Wainwright Adjusts Aeglea BioTherapeutics' Price Target to $15 from $17, Keeps Buy Rating	20-11-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Analyst Reco.

Filters